Stocks for Johnson & Johnson and Emergent BioSolutions fell in early trading Thursday amid reports that around 15 million doses of J&J’s COVID-19 vaccine …
Stocks for Johnson & Johnson and Emergent BioSolutions fell in early trading Thursday amid reports that around 15 million doses of J&J’s COVID-19 vaccine failed quality checks after an ingredients mix-up. Emergent BioSolutions was down over 13 points, or 14%, as it dealt with the fallout from the problem at its Baltimore facility. Workers conflated ingredients from the J&J vaccine and a version from AstraZeneca, which is also being produced at the plant. Both vaccines use an adenovirus-vector — essentially an inactivated virus that introduces proteins in cells that create antibodies —but the versions’ ingredients aren’t interchangeable.
